The Pennsylvania Commonwealth Court has decided a new case that may have a huge impact on cannabis licensing in the Mid-Atlantic region. The Commonwealth Court hears cases involving state and local government entities and state agencies in Pennsylvania and has heard a number of challenges regarding the administration of the 2016 Medical Marijuana Act (MMA).
We are rapidly approaching the close of 2018 and the first birthday of a regulated medical and adult-use cannabis industry in California. The transformation from a lightly regulated medical cannabis industry to a highly regulated medical and adult-use commercial market1 has been plagued by fits and starts as the regulatory agencies struggle to create a workable structure 2. The highlights for us relating to this transition have included………………
The ECDD, studying the effects of cannabis officially for only the second time since the 1950s, will present its findings to the United Nations and the public on December 7, in regard to a revision of the International Conventions’ Schedule, which currently ranks marijuana alongside heroin and crack.
Recreational cannabis hasn’t been legal for long, but a lot of ink has already been spilled about it. While the media have given extensive coverage to its potential health effects and to the impacts and ramifications of cannabis use for employers, little has been said regarding the commercialization and marketing of this new product and its accessories1 by businesses.
The revised law adopted November 23, 2018 is limited to CBD concentrates with THC levels too low to cause intoxication.
Public interest in the potential health benefits of CBD (cannabidiol) is responsible for a whole new market segment of health and wellness foods and supplements that features CBD as an ingredient. CBD is one of more than 100 cannabinoids in the cannabis plant, but unlike THC (tetrahydrocannabinol), CBD is not psychoactive and won’t get the user “high.” The CBD market is expected to top $591 million this year, and with federal protections could grow to $22 billion by 2022. Fueling this trend is scientific and anecdotal evidence of CBD’s effect on anxiety, pain, inflammation, nausea and seizures, as well as its value in fighting the opioid crisis.